Annual report pursuant to Section 13 and 15(d)

ROYALTY OBLIGATIONS NET (Details Narrative)

v3.24.1
ROYALTY OBLIGATIONS NET (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Nov. 09, 2023
Mar. 29, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Interest expense amortization     $ 121,774 $ 121,774 $ 355,662 $ 477,436 $ 477,436
Non-cash interest expense           $ 7,171,200  
Expected life of the arrangement           15 years  
Royalty agreements description           each party would purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay each (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments  
Ownership percentage           50.00%  
Minimum [Member] | Joseph Galligan [Member]              
Ownership percentage 15.00% 15.00%       15.00%  
Maximum [Member] | Joseph Galligan [Member]              
Ownership percentage 20.00% 20.00%       20.00%